Thus, modulation of TLR-9 expression has been suggested as a therapeutic target, aiming to reduce its expression in SLE to be followed by a reduction of IL-10 production which has been demonstrated to be associated with SLE disease activity. The gene discussed is TLR9; the disease is systemic lupus erythematosus.